The European Medicines Agency (EMA) has today stated that the vaccine from the British-Swedish company AstraZeneca is not related to the overall increased risk of blood clots. She stressed that the benefits outweigh the risks.
"The Committee has reached a clear scientific conclusion: a safe and effective vaccine," said Director EMA Emer Cook at a press conference after the case was dealt with by the EMA Committee on Risk Assessment of Medicinal Products (PRAC)."The Committee also concluded that the vaccine is not associated with an increased overall risk of thromboembolic events or blood clots," supplied by AFP Cook.
In a report, the EMA also stated on its website that "there is no evidence of a problem related to specific batches of vaccine or specific production sites."
However, the vaccine may be associated with very rare cases of blood clots associated with thrombocytopenia, i.e. low platelet counts (blood elements that help with clotting) with or without bleeding, including rare cases of clots in blood vessels draining blood from the brain (CVST)." informed the EMA.
According to it, the PRAC will carry out a further risk review, including a risk review with other types of COVID-19 vaccines. At the same time, close monitoring of blood clotting disorders will continue. In addition, further studies are being launched to provide "more laboratory data and evidence from the real world" added the European Medicines Agency.
On Tuesday, the EMA stated that "nothing" suggests that AstraZeneca's new corona virus vaccine may be blood clots that have been reported after vaccination from several countries. She also added that she was "fully convinced" of the benefits of this vaccine.
Vaccination with AstraZeneca vaccine has recently been suspended by several countries. This occurred after reports of blood clots in several vaccinees.
Source: TASR